• Globe Newswire

Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders

Globenewswire -

• Globe Newswire

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Globenewswire -

• Globe Newswire

 Wood Mackenzie appoints new Chief Financial Officer

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=bb6dfea7-d12f-48ff-a9d6-be87bc89823e&size=3[/img]Globenewswire -

• Globe Newswire

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

• Globe Newswire

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

• Globe Newswire

AMEC Announces New Chair

• Globe Newswire

Renewables and nascent low-carbon technologies most exposed to high interest rates

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=2cafe198-05f3-42d2-ae4d-f632867b1b68&size=3[/img]